Literature DB >> 28701047

Heart rate is a useful marker of adherence to beta-blocker treatment in hypertension.

Eva Kociánová1, Jan Václavík1, Jana Tomková2, Peter Ondra2, Jiří Jarkovský3, Klára Benešová3, Tomáš Václavík4, Monika Kamasová1, Miloš Táborský1.   

Abstract

OBJECTIVES: Suboptimal medication adherence is common among patients with hypertension. Measurements of plasma or urinary levels of antihypertensive drugs are useful, but not widely available. The aim of our study was to investigate the relation of patients' heart rates to their serum beta-blocker levels.
METHODS: We correlated 220 measurements of serum beta-blocker levels in 106 patients with apparently resistant hypertension to their corresponding office heart rate. A significant proportion, 44.6% of patients, were non-adherent to beta-blocker treatment according to serum level measurement. Non-adherent patients had significantly higher heart rates (80.9 vs. 66.6 bpm, p < .001), systolic (157.4 vs. 147.0 mm Hg, p = .002) and diastolic blood pressure (91.1 vs. 87.2 mm Hg, p = .041) in comparison to adherent patients.
RESULTS: Heart rate above 75.5 beats per minute predicted non-adherence to beta-blocker treatment with a sensitivity of 62.5%, specificity 86.8% and AUC ROC 0.802 (p < .001). Higher heart rate cutoff might be applicable for nebivolol but was not determined due to the low number of patients treated with nebivolol.
CONCLUSIONS: We concluded that heart rate was shown to be a good predictor of non-adherence to beta-blocker treatment, and might become a quick and easy measure to determine patient adherence in hypertensive patients.

Entities:  

Keywords:  Adherence; beta blockers; compliance; drug level monitoring; resistant hypertension

Mesh:

Substances:

Year:  2017        PMID: 28701047     DOI: 10.1080/08037051.2017.1346458

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  4 in total

Review 1.  Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System.

Authors:  Andrew E Levy; Carrie Huang; Allen Huang; P Michael Ho
Journal:  Curr Atheroscler Rep       Date:  2018-01-24       Impact factor: 5.113

2.  Therapeutic drug monitoring-guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence.

Authors:  Valeria Avataneo; Amedeo De Nicolò; Franco Rabbia; Elisa Perlo; Jacopo Burrello; Elena Berra; Marco Pappaccogli; Jessica Cusato; Antonio D'Avolio; Giovanni Di Perri; Franco Veglio
Journal:  Br J Clin Pharmacol       Date:  2018-08-15       Impact factor: 4.335

3.  Evidence of Nonadherence in Cases of Pseudoresistant Hypertension.

Authors:  João Marcos de Menezes Zanatta; Luciana Neves Cosenso-Martin; Valquíria da Silva Lopes; Jéssica Rodrigues Roma Uyemura; Aleandra Marton Polegati Santos; Manoel Ildefonso Paz Landim; Juan Carlos Yugar-Toledo; José Fernando Vilela-Martin
Journal:  Integr Blood Press Control       Date:  2021-02-11

Review 4.  Resistant hypertension-defining the scope of the problem.

Authors:  Richard Chia; Ambarish Pandey; Wanpen Vongpatanasin
Journal:  Prog Cardiovasc Dis       Date:  2019-12-19       Impact factor: 11.278

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.